

**FULBRIGHT & JAWORSKI L.L.P.**

A REGISTERED LIMITED LIABILITY PARTNERSHIP

666 FIFTH AVENUE, 31ST FLOOR

NEW YORK, NEW YORK 10103-3198

WWW.FULBRIGHT.COM

**FACSIMILE TRANSMISSION**

DATE: February 28, 2003

MATTER NUMBER: 10105485

RECIPIENT(S):	FAX NO.:	PHONE NO.:
Examiner D. Wortman USPTO, Group 1648	703-872-9306	

**FAX RECEIVED**

MAR 3 2003

**OFFICIAL** GROUP 1600

FROM: Norman Hanson USER ID: NH01030 FLOOR: 24

PHONE: (212) 318-3168 FAX: (212) 318-3400

RE: HUBR 1067.3

NUMBER OF PAGES WITH COVER PAGE:

Message:

**CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL  
AT \_\_\_\_\_ AS SOON AS POSSIBLE.

## VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on February 28, 2003.

Fulbright &amp; Jaworski L.L.P.

*Lawrence Oles*

HUBR 1067.3 (10105485) - NDH

#9  
Amtd.c  
3/28/02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Christoph Seidel, et al.  
 Serial No. : 09/896,032  
 Filed : June 29, 2001  
 For : METHOD FOR DETERMINING EARLY HCV SEROCONVERSION  
 Art Unit : 1648  
 Examiner : D. C. Wortman

February 28, 2003

Hon. Commissioner of Patents  
 and Trademarks  
 Washington, D.C. 20231

AMENDMENT  
UNDER 37 C.F.R. §1.111)

This amendment is submitted in response to the office action dated December 12, 2002.

Please amend this application as follows:

IN THE CLAIMS

Cancel claims 27-36 and replace them by claims 39-48, which follow. Replace claim 38 by the following, and add claim 49:

*Sub-D*  
*Cancel*

Claim 38: A method for determining seroconversion in a human subject infected with hepatitis C virus, comprising: (i) incubating a sample taken from said subject, with a first solid phase bound polypeptide, and a second, labeled polypeptide which is in solution, wherein the amino acid sequence of said first and second polypeptides are found in hepatitis C virus protein, NS3 region, said incubation being carried out under reducing conditions, to determine binding of a hepatitis C virus specific antibody to both of said first and second polypeptides, and (ii) comparing results from (i) to results obtained at a previous point in time from said subject which were negative for presence of antibodies to hepatitis C virus protein NS3 region, wherein a difference in (i) as compared to results obtained from said

03/05/2003 F1THOMAS2 00000001 500624 09896032

252081601  
01 FC:1201

84.00 CH